Q-linea AB (publ) (STO:QLINEA)

Market Cap	426.35M
Revenue (ttm)	10.73M
Net Income (ttm)	-188.37M
Shares Out	18.95M
EPS (ttm)	-38.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,681
Average Volume	7,170
Open	23.41
Previous Close	23.60
Day's Range	22.50 - 23.41
52-Week Range	22.50 - 1,170.00
Beta	0.72
RSI	26.66
Earnings Date	Feb 6, 2026

About Q-linea AB

Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, European Union, the Middle East, and the United States. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture unit for incu...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2007
• Employees: 94
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: QLINEA

Financial Performance

In 2024, Q-linea AB's revenue was 4.14 million, a decrease of -25.21% compared to the previous year's 5.53 million. Losses were -216.87 million, -5.45% less than in 2023.